Autophagy inducers represent new promising agents for the treatment of a wide range of medical illnesses. However, safe autophagy inducers for clinical applications are lacking. Inhibition of cdc2-like kinase 1 (CLK1) was recently found to efficiently induce autophagy. Unfortunately, most of the known CLK1 inhibitors have unsatisfactory selectivity. Herein, we report the discovery of a series of new CLK1 inhibitors containing the 1H-[1,2,3]triazolo[4,5-c]quinoline scaffold. Among them, compound 25 was the most potent and selective, with an IC₅₀ value of 2 nM against CLK1. The crystal structure of CLK1 complexed with compound 25 was solved, and the potency and kinase selectivity of compound 25 were interpreted. Compound 25 was able to induce autophagy in in vitro assays and displayed significant hepatoprotective effects in the acetaminophen (APAP)-induced liver injury mouse model. Collectively, due to its potency and selectivity, compound 25 could be used as a chemical probe or agent in future mechanism-of-action or autophagy-related disease therapy studies.

中文翻译：

---

发现作为新型自噬诱导剂的Cdc2样激酶1（CLK1）的有效和选择性抑制剂。

自噬诱导剂代表了用于治疗多种医学疾病的新的有前途的药物。但是，缺乏用于临床应用的安全自噬诱导剂。最近发现抑制cdc2样激酶1（CLK1）可以有效诱导自噬。不幸的是，大多数已知的CLK1抑制剂的选择性都不令人满意。在这里，我们报告发现了一系列新的包含1 H- [1,2,3]三唑[4,5- c ]喹啉骨架的CLK1抑制剂。其中，化合物25是最有效和最具选择性的，相对于CLK1的IC ₅₀值为2 nM。与化合物络合CLK1的晶体结构25解决了，并且效力和化合物的激酶选择性25被解释。化合物25在体外测定中能够诱导自噬，并且在对乙酰氨基酚（APAP）诱导的肝损伤小鼠模型中显示出显着的保肝作用。总体而言，由于其效价和选择性，化合物25可用作未来的作用机理或自噬相关疾病治疗研究的化学探针或试剂。